NCT05570552

Brief Summary

Almost 3 billion people worldwide, including 89% people in Bangladesh, are exposed to harmful household air pollutants (HAP) emitted from combustion of biomass (wood, agricultural residue, cow dung, etc.) fuel use for cooking. While health risks associated with air-pollution have been reasonably well-studied in developed countries, there is little evidence on health benefits achievable by HAP reduction through clean fuel use, especially in low- and middle-income countries (LMICs). Earlier the investigators showed that Liquid Petroleum Gas (LPG) for 24 months, reduced personal PM2.5 exposure by 58.17 percent which induced novel changes in immune and inflammatory responses in the participants; however cardiopulmonary markers remained relatively stable in post-intervention assessment. In this study, the investigators aim to evaluate the effects of mobile phone based (mHealth) Behavioural Change Communication (BCC) intervention on adoption and exclusive use of LPG. The investigators also aimed to observe whether long-term effects of HAP reduction can impact the subclinical measures of cardio-vascular and pulmonary dysfunction and regulate innate and inflammatory immune function among women and children in semi-rural settings in Bangladesh. The investigators will also investigate the influence of exposure to HAP on antibody response to vaccines (adaptive immunity). The BCC intervention will be provided by conducting a large household level randomized controlled trial by educational intervention using mHealth based technology. In addition, the investigators will continue following the cohort and will conduct rigorous and repeated personalized (24 hours) and area (over 5 days) assessments of PM2.5 and black carbon (BC) exposure to examine the long-term effects of HAP reduction on subclinical measures of cardio-pulmonary and immune dysfunction including effect of HAP exposure on antibody response to vaccine.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for not_applicable

Timeline
13mo left

Started Jun 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Jun 2023Jun 2027

First Submitted

Initial submission to the registry

August 29, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 6, 2022

Completed
9 months until next milestone

Study Start

First participant enrolled

June 20, 2023

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2027

Last Updated

March 22, 2024

Status Verified

March 1, 2024

Enrollment Period

3.9 years

First QC Date

August 29, 2022

Last Update Submit

March 20, 2024

Conditions

Keywords

Mobile based Behavioral Change Communication interventionHousehold air pollution reductionCardiopulmonary functionImmune functionClean fuel LPG

Outcome Measures

Primary Outcomes (18)

  • Personal air pollution

    Measurement of personal air pollution (PM2.5 and BC level) by personal air pollution monitoring device

    Pre-intervention

  • Personal air pollution

    Measurement of personal air pollution (PM2.5 and BC level) by personal air pollution monitoring device

    Two-year post intervention

  • Ambient air pollution

    Measurement of ambient air pollution (PM2.5) by ambient air monitoring device

    Pre-intervention

  • Ambient air pollution

    Measurement of ambient air pollution (PM2.5) by ambient air monitoring device

    Two-year post intervention

  • Lung function assessment by spirometry

    Lung function assessment by spirometry

    Pre-intervention

  • Lung function assessment by spirometry

    Lung function assessment by spirometry

    Two-year post intervention

  • Assessment lung pathology by chest X-ray and High-resolution Computed tomography

    Lung pathology will be assessed by chest X-ray for all participants and high-resolution Computed tomography of the chest (HRCT) will be performed in selected participants.

    Pre-intervention

  • Assessment lung pathology by chest X-ray and High-resolution Computed tomography

    Lung pathology will be assessed by chest X-ray for all participants and high-resolution Computed tomography of the chest (HRCT) will be performed in selected participants.

    Two-year post intervention

  • Measurement of cardiovascular disease (CVD) markers by measuring blood pressure

    Preclinical markers of CVD assessment by blood pressure

    Pre-intervention

  • Measurement of cardiovascular disease (CVD) markers by measuring blood pressure

    Preclinical markers of CVD assessment by blood pressure

    Two-year post intervention

  • Measurement of cardiovascular disease (CVD) markers by performing EKG

    Preclinical markers of CVD assessment by EKG

    Pre-intervention

  • Measurement of cardiovascular disease (CVD) markers by performing EKG

    Preclinical markers of CVD assessment by EKG

    Two-year post intervention

  • Evaluation of metabolic markers (diabetes) in blood at baseline.

    Assessment of metabolic dysfunction by measuring HbA1c

    Pre-intervention

  • Evaluation of metabolic markers (diabetes) in blood after intervention.

    Assessment of metabolic dysfunction by measuring HbA1c

    Two-year post intervention

  • Evaluation of metabolic markers (CVD) in blood.

    Assessment of metabolic dysfunction by measuring fasting lipid profile.

    Pre-intervention

  • Evaluation of metabolic markers (CVD) in blood.

    Assessment of metabolic dysfunction by measuring fasting lipid profile.

    Two-year post intervention

  • Assessment of immune function in blood cells

    Immune function will be assessed by phenotyping using flowcytometry

    Pre-intervention

  • Assessment of immune function in blood cells

    Immune function will be assessed by phenotyping using flowcytometry

    Two-year post intervention

Study Arms (2)

mHealth arm

EXPERIMENTAL

mHealth arm will receive mobile phone based behavior change communication intervention to exclusively use clean fuel LPG for domestic cooking.

Behavioral: mHealth based behavioral change communication intervention

Control arm

NO INTERVENTION

Control arm will receive no mHealth based intervention.

Interventions

We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.

Also known as: value sensitive design (VSD), Fogg Behavior Model (FBM), System Usability Scale (SUS)
mHealth arm

Eligibility Criteria

Age25 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants in the previous GEOHEALTH round-I study
  • Aged between 25 and 70 years
  • Live in biomass-using home with traditional stoves
  • Non-smoker and live with non-smokers
  • Exposed to \<10 µg/L of water arsenic

You may not qualify if:

  • Known to have immune related illness or taking any prescription medication (particularly those that suppress or enhance immune function)
  • Known to have any clinical events of CVD or lung disease, including stroke or coronary heart disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

International Centre for Diarrhoeal Diseases Research, Bangladesh

Dhaka, 1212, Bangladesh

RECRUITING

Central Study Contacts

Rubhana Raqib, PhD

CONTACT

Mohammad Yunus, MBBS, M.Sc.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 29, 2022

First Posted

October 6, 2022

Study Start

June 20, 2023

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

June 1, 2027

Last Updated

March 22, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will share

All data collected of the proposed study will be made fully available to any bonafide researcher. In general, the investigators will follow the data sharing plan developed and practiced by the NIH-funded grantees. Any data request by external researchers will be reviewed by the PIs and the AOC and the requested specific data will be made available to the through a secured web-based interface developed specifically for this project. In general, data will be made available six months after the manuscript reporting results from those specific sets of data are accepted for publication and all data requests will be processed within six months from the receipt of the request in writing. Any data requests with potential conflicts will be reviewed and decided by the AOC.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will be available 6 months after manuscripts accepted for publication

Locations